References
- Giacomelli C, Daniele S, Martini C. Potential biomarkers and novel pharmacological targets in protein aggregation-related neurodegenerative diseases. Biochem Pharmacol. 2017;2952:30047–30053.
- Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839–840.
- Miraglia F, Betti L, Palego L, et al. Parkinson’s disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge. Cent Nerv Syst Agents Med Chem. 2015;15:109–116.
- Dickson DW. Parkinson’s disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med. 2012;2:2.
- Rochet JC. Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev Mol Med. 2007;9:1–34.
- Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med. 2004;10:S10–S17.
- Cookson MR. Alpha-Synuclein and neuronal cell death. Mol Neurodegener. 2009;4:9.
- Sardi SP, Cedarbaum JM, Brundin P. Targeted therapies for Parkinson’s disease: from genetics to the clinic. Mov Disord. 2018;33:684–696.
- ClinicalTrials.gov [Internet]. Single ascending dose study of MEDI1341 in healthy volunteers; cited 2018 Sept 6. Available fromhttps://clinicaltrials.gov/ct2/show/NCT03272165.
- ClinicalTrials.gov [Internet]. Multiple dose safety study of NPT088 in patients with mild to moderate probable Alzheimer’s disease. [cited 2018 Sep 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT03008161?term=NPT088&rank=1.
- ClinicalTrials.gov [Internet]. Follow-up study to assess a second boost immunization with AFFITOPE® PD01A with regard to safety and clinical activity (AFF008AA). [cited 2018 Sep 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT02618941?term=PD01A&rank=1.
- ClinicalTrials.gov [Internet]. Phase 1 study of NPT200-11 in healthy subjects. [cited 2018 Sep 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT02606682?term=NPT200-11&rank=1.
- ClinicalTrials.gov [Internet]. Evaluating the safety, pharmacokinetics, and pharmacodynamics of BIIB054 in participants with Parkinson’s disease (SPARK). [cited 2018 Sep 6]. https://clinicaltrials.gov/ct2/show/NCT03318523?term=BIIB054&rank=1.
- ClinicalTrials.gov [Internet]. A study to evaluate the efficacy of prasinezumab (RO7046015/PRX002) in participants with early Parkinson’s disease (PASADENA). [cited 2018 Sep 6]. https://clinicaltrials.gov/ct2/show/NCT03100149?term=RO7046015&rank=1.
- Hall A, Proviwith ns L, Maccoss M. Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation. WO2018138088. 2018.
- Stocking E, Wrasidlo W Heteroaryl amides as inhibitors of protein aggregation. WO2015116663A1. 2015.
- Caruana M, Hogen T, Levin J, et al. Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds. FEBS Lett. 2011;585:1113–1120.
- Zhu M, Rajamani S, Kaylor J, et al. The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J Biol Chem. 2004;279:26846–26857.
- Jha NN, Ghosh D, Das S, et al. Effect of curcumin analogs on α-synuclein aggregation and cytotoxicity. Sci Rep. 2016;6:28511.
- Bieschke J, Russ J, Friedrich RP, et al. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci U S A. 2010;107:7710–7715.
- Xu Y, Zhang Y, Quan Z, et al. Epigallocatechin Gallate (EGCG) inhibits alpha-synuclein aggregation: a potential agent for Parkinson’s disease. Neurochem Res. 2016;41:2788–2796.
- Tellone E, Galtieri A, Russo A, et al. Resveratrol: a focus on several neurodegenerative diseases. Oxid Med Cell Longev. 2015;2015:392169.
- Oertel W, Schulz JB. Current and experimental treatments of Parkinson disease: A guide for neuroscientists. J Neurochem. 2016;139 Suppl 1:325–337.
- Wagner J, Ryazanov S, Leonov A, et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease. Acta Neuropathol. 2013;125:795–813.
- Levin J, Schmidt F, Boehm C, et al. The oligomer modulator Anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathol. 2014;127:779–780.
- Wrasidlo W, Stocking E, Hall A, et al. Bis-heteroaryl derivatives as modulators of protein aggregation. WO2017020010A1. 2017.
- Hall A, Maccoss M Alkoxy bis-heteroaryl deriviatives as modulators of protein aggregation. WO2018138085A1. 2018.
- Hall A, Bis-heteroaryl derivatives as modulators of protein aggregation. WO2018138086. 2018.